SCOPUS 정보 검색 플랫폼

Volumn 8, Issue 9, 2002, Pages 2775-2781

Maintenance biotherapy for metastatic melanoma with interleukin-2 and Granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy

(12) O'Day, Steven J a Boasberg, Peter D a Piro, Lawrence a Kristedja, Timothy S a Wang, He Jing a Martin, Maureen a Deck, Regina a Ames, Patricia a Shinn, Kelly a Kim, Hannah a Fournier, Patricia a Gammon, Guy b

a JOHN WAYNE CANCER INSTITUTE (United States)

b CancerVax Corporation (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; INJECTION PAIN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MALE; MELANOMA; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RIGOR; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HYPERTHYROIDISM; INTERLEUKIN-2; LIFE TABLES; MELANOMA; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TAMOXIFEN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036719062 PISSN: 10780432 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (62)

References (25)

1
- 0027486041
- Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2A for metastatic melanoma
- (1993) J. Clin. Oncol. , vol.11 , pp. 2173-2180
- Khayat, D.¹ Borel, C.² Tourani, J.M.³ Benhammouda, A.⁴ Antoine, E.⁵ Rixe, O.⁶ Vuillemin, E.⁷ Bazex, P.A.⁸ Thill, L.⁹ Franks, R.¹⁰

2
- 0029906912
- Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and integeron-α
- (1996) Ann. Oncol. , vol.7 , pp. 827-835
- Legha, S.S.¹ Ring, S.² Bedikian, A.³ Plager, C.⁴ Eton, O.⁵ Buzaid, A.C.⁶ Papadopoulos, N.⁷

3
- 0026734180
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma
- (1992) J. Clin. Oncol. , vol.10 , pp. 1338-1343
- Richards, J.M.¹ Menta, N.² Ramming, K.³ Skosey, P.⁴

4
- 0031064875
- Outpatient chemoimmunotherapy for the treatment of metastatic melanoma
- (1997) Semin. Oncol. , vol.24 , pp. S44-S48
- Thompson, J.A.¹ Gold, P.J.² Fefer, A.³

5
- 0034043168
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2b in patients with metastatic melanoma
- (2000) Clin. Cancer Res. , vol.6 , pp. 2201-2208
- McDermott, D.F.¹ Mier, J.W.² Lawrence, D.P.³ Van den Brink, M.R.⁴ Clancy, M.A.⁵ Ruben, K.M.⁶ Atkins, M.B.⁷

6
- 0031424902
- Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience
- (1997) Cancer J. Sci. Am. , vol.3 , pp. S9-S15
- Legha, S.S.¹ Ring, S.² Eton, O.³ Bedikian, A.⁴ Plager, C.⁵ Papadopoulos, N.⁶

7
- 0030937204
- Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon α and chemotherapy
- (1997) Semin. Oncol. , vol.24 , pp. S39-S43
- Legha, S.S.¹

8
- 0031805726
- Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma
- (1998) J. Clin. Oncol. , vol.16 , pp. 1752-1759
- Legha, S.S.¹ Ring, S.² Eton, O.³ Bedikian, A.⁴ Buzaid, A.C.⁵ Plager, C.⁶ Papadopoulous, N.⁷

9
- 0032850026
- Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
- (1999) J. Clin. Oncol. , vol.17 , pp. 2752-2761
- O'Day, S.J.¹ Gammon, G.² Boasberg, P.D.³ Martin, M.A.⁴ Kristedja, T.S.⁵ Guo, M.⁶ Stern, S.⁷ Edwards, S.⁸ Fournier, P.⁹ Weisberg, M.¹⁰ Cannon, M.¹¹ Fawzy, N.W.¹² Johnson, T.D.¹³ Essner, R.¹⁴ Foshag, L.J.¹⁵ Morton, D.L.¹⁶

10
- 0027531423
- Selective modulation of human natural killer cells in vivo after prolonged infusion of low-dose recombinant interleukin-2
- (1993) J. Clin. Investig. , vol.91 , pp. 123-132
- Caligiuri, M.A.¹ Murray, C.² Robertson, M.J.³ Wang, E.⁴ Cochran, K.⁵ Cameron, C.⁶ Schwa, P.⁷ Ross, M.E.⁸ Klumpp, T.R.⁹ Soiffer, R.J.¹⁰ Smith, K.A.¹¹ Ritz, J.¹²

11
- 0029122468
- Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: Biological effects and clinical implications
- (1995) Cancer Biother. , vol.10 , pp. 195-203
- Guida, M.¹ Abbate, I.² Casamassima, A.³ Musci, M.D.⁴ Latorre, A.⁵ Lorusso, V.⁶ Correale, M.⁷ De Lena, M.⁸

12
- 0029590213
- Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
- (1995) J. Immunother. Emphas. Tumor Immunol. , vol.18 , pp. 188-195
- Angevin, E.¹ Valteau-Couanet, D.² Farace, F.³ Dietrich, P.Y.⁴ Lecesne, A.⁵ Triebel, F.⁶ Escudier, B.⁷

13
- 0028266553
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
- (1994) JAMA , vol.271 , pp. 907-913
- Rosenberg, S.A.¹ Yang, J.C.² Topalian, S.L.³ Schwartzentruber, D.J.⁴ Weber, J.S.⁵ Parkinson, D.R.⁶ Seipp, C.A.⁷ Einhorn, J.H.⁸ White, D.E.⁹

14
- 0033024863
- High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
- (1999) J. Clin. Oncol. , vol.17 , pp. 2105-2116
- Atkins, M.B.¹ Lotze, M.T.² Dutcher, J.P.³ Fisher, R.I.⁴ Weiss, G.⁵ Margolin, K.⁶ Abrams, J.⁷ Sznol, M.⁸ Parkinson, D.⁹ Hawkins, M.¹⁰ Paradise, C.¹¹ Kunkel, L.¹² Rosenberg, S.A.¹³

15
- 0000645524
- Efficacy of interleukin-2 in the treatment of metastatic melanoma: Systematic review and meta-analysis
- (1998) Cancer Ther. , vol.1 , pp. 168-173
- Allen, I.E.¹ Kupelnick, B.² Kumashiro, M.³ Luo, D.⁴ Ross, S.D.⁵ Wolin, M.J.⁶

16
- 0022478367
- Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
- (1986) Science (Wash. DC) , vol.232 , pp. 506-508
- Grabstein, K.H.¹ Urdal, D.L.² Tushinski, R.J.³ Mochizuki, D.Y.⁴ Price, V.L.⁵ Cantrell, M.A.⁶ Gillis, S.⁷ Conlon, P.J.⁸

17
- 0033998594
- Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
- (2000) J. Clin. Oncol. , vol.18 , pp. 1614-1621
- Spitler, L.E.¹ Grossbard, M.L.² Ernstoff, M.S.³ Silver, G.⁴ Jacobs, M.⁵ Hayes, F.A.⁶ Soong, S.J.⁷

18
- 0025314129
- Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)
- (1990) Cancer Immunol. Immunother. , vol.31 , pp. 231-235
- Masucci, G.¹ Ragnhammar, P.² Wersall, P.³ Mellstedt, H.⁴

19
- 0023821508
- Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor
- (1988) J. Immunol. , vol.141 , pp. 519-526
- Santoli, D.¹ Clark, S.C.² Kreider, B.L.³ Maslin, P.A.⁴ Rovera, G.⁵

20
- 0029916896
- Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: A phase IB study
- (1996) Clin. Cancer Res. , vol.2 , pp. 319-330
- Schiller, J.H.¹ Hank, J.A.² Khorsand, M.³ Storer, B.⁴ Borchert, A.⁵ Huseby-Moore, K.⁶ Burns, D.⁷ Wesly, O.⁸ Albertini, M.R.⁹ Wilding, G.¹⁰ Sondel, P.M.¹¹

21
- 0342368610
- Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma and renal cell carcinoma
- (2000) Clin. Cancer Res. , vol.6 , pp. 1267-1272
- De Gast, G.C.¹ Klumpen, H.J.² Vyth-Dreese, F.A.³ Kersten, M.J.⁴ Verra, N.C.⁵ Sein, J.⁶ Batchelor, D.⁷ Nooijen, W.J.⁸ Schornagel, J.H.⁹

22
- 0032850026
- Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
- (1999) J. Clin. Oncol. , vol.17 , pp. 2752-2761
- O'Day, S.J.¹ Gammon, G.² Boasberg, P.D.³ Martin, M.A.⁴ Kristedja, T.S.⁵ Guo, M.⁶ Stem, S.⁷ Edwards, S.⁸ Fournier, P.⁹ Weisberg, M.¹⁰ Cannon, M.¹¹ Fawzy, N.W.¹² Johnson, T.D.¹³ Essner, R.¹⁴ Foshag, L.J.¹⁵ Morton, D.L.¹⁶

23
- 0035425456
- High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma
- (2001) Cancer (Phila.) , vol.92 , pp. 609-619
- O'Day, S.J.¹ Boasberg, P.D.² Kristedja, T.S.³ Martin, M.⁴ Wang, H.J.⁵ Fournier, P.⁶ Cabot, M.⁷ DeGregorio, M.W.⁸ Gammon, G.⁹

24
- 0031718717
- Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
- (1998) J. Clin. Oncol. , vol.16 , pp. 2921-2929
- Keilholz, U.¹ Conradt, C.² Legha, S.S.³ Khayat, D.⁴ Scheibenbogen, C.⁵ Thatcher, N.⁶ Goey, S.H.⁷ Gore, M.⁸ Dorval, T.⁹ Hancock, B.¹⁰ Punt, C.J.¹¹ Dummer, R.¹² Avril, M.F.¹³ Brocker, E.B.¹⁴ Benhammouda, A.¹⁵ Eggermont, A.M.¹⁶ Pritsch, M.¹⁷

25
- 0034669656
- Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials
- (2000) J. Clin. Oncol. , vol.18 , pp. 3782-3793
- Manola, J.¹ Atkins, M.² Ibrahim, J.³ Kirkwood, J.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.